Citation: Koudinov AR, Berezov TT (2005) Cholesterol, Statins, and Alzheimer Disease. PLoS Med 2(3): e81. https://doi.org/10.1371/journal.pmed.0020081
Published: March 29, 2005
Copyright: © 2005 Koudinov and Berezov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests: ARK serves as founding and managing editor of Neurobiology of Lipids (ISSN 1683-5506), an unpaid position. ARK and TTB declare that they have no competing financial interests.
After reading the excellent research article by Pedrini et al.  and the associated synopsis , one may conclude that the only pathway of statins' effect on Alzheimer disease (AD) is the regulation of amyloid precursor protein (APP) processing and amyloid-ß protein (Aß) generation. The moderation is provided in the research article's patient summary, reminding that “statins are likely to influence the risk for Alzheimer disease by several different pathways.” What are these other pathways? It is essential to note that in addition to APP processing and Aß chemistry being modulated by statins, fine tuning of cholesterol homeostasis also affects cholinergic function, ionotropic and metabotropic receptors, tau phosphorylation, neural oxidative stress reactions, and other features of neurodegeneration (reviewed in ). Moreover, precise regulation of neural cholesterol dynamics and supply is itself essential for synapse function, plasticity, and behaviour . These data suggest that in addition to its role in sporadic AD, cholesterol homeostasis break is the unifying primary cause of neuromuscular diseases, Niemann-Pick type C disease, and Down syndrome, and explains why rare cases of familial AD (associated with mutations in APP and presenilin genes) are translated into Alzheimer's via membrane cholesterol sensitivity of APP processing by secretases and Aß generation. Also important, is the synopsis's  apparently outdated dividing of APP processing into “harmful” (Aß-generating) and “healthy” (non-amyloidogenic). One should be cautious in calling Aß a harmful molecule. This is because several recent studies have illuminated an essential function for amyloidogenic processing of APP and Aß in neurons  and synapses . In this context, the reciprocal effect of Aß on cholesterol synthesis, cellular uptake, efflux, and esterification, and its relation to the experimental restoration of long-term potentiation (LTP, a synaptic plasticity measure) may represent one of the poorly comprehended physiological functions of Aß [6,7].
- 1. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, et al. (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2: e18.
- 2. (2005) How statins may protect against Alzheimer disease. PLoS Med 2: e22.
- 3. Koudinov AR, Koudinova NV (2004) Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J Neurol Sci.
- 4. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA (2003) The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 23: 5531–5535.
- 5. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, et al. (2003) APP processing and synaptic function. Neuron 27: 925–937.
- 6. Koudinov AR, Koudinova NV (2003) Amyloid beta protein restores hippocampal long term potentiation: A central role for cholesterol? Neurobiol Lipids 1: 8. Available at: http://neurobiologyoflipids.org/content/1/8/. Accessed 10 February 2005.
- 7. Koudinov AR, Berezov TT (2004) Alzheimer's amyloid beta (Aß) is an essential synaptic protein, not neurotoxic junk. Acta Neurobiol Exp 64: 71–79. Available at: http://www.nencki.gov.pl/pdf/an/vol64/koudin.pdf. Accessed 10 February 2005.